Momelotinib versus best available therapy in patients with...

  • Main
  • 2017 / 12
  • Momelotinib versus best available therapy in patients with...

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Harrison, Claire N, Vannucchi, Alessandro M, Platzbecker, Uwe, Cervantes, Francisco, Gupta, Vikas, Lavie, David, Passamonti, Francesco, Winton, Elliott F, Dong, Hua, Kawashima, Jun, Maltzman, Julia D,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
The Lancet Haematology
DOI:
10.1016/S2352-3026(17)30237-5
Date:
December, 2017
File:
PDF, 533 KB
english, 2017
Conversion to is in progress
Conversion to is failed